BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8701813)

  • 1. Molecular research in cancer: future clinical applications.
    Ratliff TL
    Acta Urol Belg; 1996 May; 64(2):53-5. PubMed ID: 8701813
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene therapy approaches in urologic oncology.
    Vieweg J; Gilboa E
    Surg Oncol Clin N Am; 1995 Apr; 4(2):203-18. PubMed ID: 7796281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous neoplastic isto-cryoprecipitates as immuno-stimulating treatment in 100 urological cancer patients.
    Marten-Perolino R; Cocimano V; Botto A; Buffa G; Riggi E; Trapani C
    J Exp Pathol; 1987; 3(4):587-92. PubMed ID: 3454806
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular engineering of the antitumor immune response.
    Pardoll DM; Golumbek P; Levitsky H; Jaffee L
    Bone Marrow Transplant; 1992; 9 Suppl 1():182-6. PubMed ID: 1387016
    [No Abstract]   [Full Text] [Related]  

  • 6. Ovarian tumour antigens as potential targets for immune gene therapy.
    Kuiper M; Peakman M; Farzaneh F
    Gene Ther; 1995 Jan; 2(1):7-15. PubMed ID: 7712335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity.
    van der Veken LT; Hoogeboom M; de Paus RA; Willemze R; Falkenburg JH; Heemskerk MH
    Gene Ther; 2005 Dec; 12(23):1686-95. PubMed ID: 16034453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of antigen recognition by T lymphocytes. Implications for vaccines.
    Berzofsky JA
    J Clin Invest; 1988 Dec; 82(6):1811-7. PubMed ID: 2974044
    [No Abstract]   [Full Text] [Related]  

  • 9. Basic overview of current immunotherapy approaches in urologic malignancy.
    Drake CG
    Urol Oncol; 2006; 24(5):413-8. PubMed ID: 16962493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of prostate cancer.
    Doehn C
    Eur Urol; 2008 Apr; 53(4):681-3; discussion 684-5. PubMed ID: 18248878
    [No Abstract]   [Full Text] [Related]  

  • 11. [Peptide-pulsed dendritic cell therapy].
    Takaue Y; Tanosaki R; Tobisu K
    Nihon Rinsho; 2000 Jul; 58 Suppl():295-8. PubMed ID: 11022733
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetically modified tumour vaccines--where we are today.
    Nawrocki S; Mackiewicz A
    Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular targets for development of cancer immunotherapy].
    Kawakami Y
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828
    [No Abstract]   [Full Text] [Related]  

  • 14. The systemic therapy of urologic cancer.
    Marsh JC
    Conn Med; 1980 Apr; 44(4):217-24. PubMed ID: 7371401
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immunotherapy of invasive cancer of the urinary bladder].
    Kharchenko VP; Kaprin AD; Ivanov SA; Klimenko AA
    Vopr Onkol; 2006; 52(6):659-62. PubMed ID: 17338244
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells for specific cancer immunotherapy.
    Meidenbauer N; Andreesen R; Mackensen A
    Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
    Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.